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ABSTRACT
COMPARISON OF LIQUID-LIQUID EXTRACTION AND SOLID PHASE
EXTRACTION OF MEPHEDRONE
by Brittany Simone Love
May 2013
Legal high drugs are modified scheduled drugs. As with any new drug,
researchers have to conduct studies to gather information about the drug. The problem
with obtaining accurate information on new drugs is that by the time information is
gathered, drug abusers and street chemists have developed new ones. Comparing
designer drugs to their illegal counterparts is often helpful in that it can provide a starting
point. Mephedrone is a new designer drug that has become a problem over the past few
years. Often marketed as bath salts and plant food, mephedrone has become the
knockoff replacement for amphetamines.
This experiment focused on comparing liquid-liquid extraction to solid phase
extraction to determine if there was a difference and which was more efficient. Synthetic
urine samples were spiked with mephedrone, extracted using both methods, and analyzed
with GC-MS. Spiked synthetic urine samples were also analyzed to determine the limit
of detection for mephedrone.
A T-ratio test determined that there is less than a 5% chance that LLE and SPE
are the same for extracting mephedrone. The t ratios for extracting 0.5µg/mL via LLE
and SPE were 5.567 and 6.542, which were above the level of significance t value 2.086.
After determining that the methods were statistically different, the percent recovery of
each method was observed. The percent recovery of SPE was higher than that of LLE for
11

0.5µg/mL, making SPE the better method. For 2.0µg/mL SPE percent recovery was less
than LLE, proving LLE to be better in this case.
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CHAPTER I
INTRODUCTION
Designer Drugs
Various drug regulations continue to stir up conflict within a society of drug
abusers. As a result, these abusers have found ways to avoid the consequences of law
while simultaneously acquiring the drugs they desire. These altered substances,
commonly known as designer drugs, are formulated to bypass the laws that prohibit their
counterparts while mimicking similar effects. Because many designer drugs are not
controlled under the Controlled Substances Act, they are referred to as Legal highs, but
are still considered to be drugs of abuse. Most of these drugs are controlled under the
Federal Analog Act of Controlled Substances Act due to their being derived from other
controlled substances (Drugs of Abuse, 2011).
Due to the lack of availability and purity of common drugs of abuse, clandestine
laboratories began producing and selling mephedrone. Mephedrone is a synthetic
derivative of cathinone, an active ingredient found in Khat (Drugs of Abuse, 2011 ). Also
known as plant food or bath salts and often sold online labeled "not for human
consumption," mephedrone has become the new drug of choice and interest. The recent
spark of mephedrone use appears to have originated primarily in the United Kingdom and
eventually began to make headlines in the United States. With increasing popularity and
emergency room reports, there have been numerous case studies on mephedrone to
determine its effects and toxicity. Although mephedrone has now been scheduled under
the Controlled Substances Act as a Schedule I drug, there is still much to be known about
this designer drug.
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Development of methods for analyzing designer drugs is crucial to the discipline
of toxicology. Effective extraction methods, analysis, and toxic research play a huge role
in keeping up with the constantly growing and changing drug field. Just as easily as
ecstasy and amphetamines were replaced with mephedrone, mephedrone will be replaced
with another designer drug. The challenge with developing methodologies for designer
drugs is there is usually no previous or current data on the drug. Without established
knowledge or reference standards to compare to, analysts seem to fall a step behind
clandestine laboratories. Research on methods, such as extractions, is beneficial in that it
can cut down on time that is spent on methods and techniques that are not productive.
For the determination of mephedrone toxicity, sample preparations as well as
proper extraction methods from biological fluids are an important factor. Extractions
have a direct effect on the sensitivity and quantization of drug analysis. An efficient
method of extraction should possess high recovery and reproducibility. Extractions are
the transfer of an analyte from one miscible phase to another phase and are used to
separate the analyte from mediums such as blood, urine, or bile (Harris, 2007). Based
around pH and polarity, a drug's pKa is one of the determining factors for choosing an
extraction solvent that the analyte can be partitioned in. The pKa is the negative
logarithm of an acid dissociation constant and describes how an acid ionizes in solution
(Harris, 2007). If the pKa is small, the acid is completely ionized and is a strong acid. A
large pKa correlates to a weak acid, meaning that the acid is partially ionized. The
Henderson-Hasselbach equation is used to determine an analyte's pH by expressing the
ratio of ionized to unionized ions in relation to its pKa.
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Before a drug can be analyzed, it has to be removed from its matrix. Liquidliquid extractions and solid phase extractions are the most commonly used methods to
separate a drug from its matrix. Liquid-liquid extraction (LLE) is the use of two
immiscible liquids to extract a drug of interest in a liquid in which it is miscible.
Depending on the drug's pKa, a buffer is added to the matrix to convert the drug to its
unionized form. Once in its unionized form, the drug can be separated from the matrix
with the addition of an extraction solvent that is polar enough to extract the drug of
interest. After the solvent is allowed to mix with the sample, the sample is centrifuged to
separate the organic solvent from the aqueous layer. The volatile organic extract is
removed and allowed to dry, leaving only the drug of interest behind. Now that the drug
has been isolated, it can be analyzed.
Solid phase extractions (SPE) use columns with a stationary phase to trap the drug
of interest while separating it from its matrix. The same concept with LLE of pH and
pKa drive the separating factors of SPE, except that SPE contains an absorbent solid. The
solid phase is made of sorbent silica that has an affinity for the drug of interest, binding
it, while allowing unwanted waste materials to pass by. Before separating the drug from
its matrix, the columns are conditioned with methanol (MeOH) and water to remove
absorbed organic material in the column. The sample containing the drug of interest is
poured into the column allowing the drug to adhere to the stationary phase. Columns
have different types of systems to help materials pass through the column; there are
columns that allow the materials to flow by gravity, or with negative or positive pressure
systems. Once the drug is contained in the column, the sample is washed with weak
solvents and water to removed unwanted polar solutes. A strong organic solvent is used
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to elute the strongly bound drug from the stationary phase. The desired eluent is eluted in
its own tube and evaporated to dryness, leaving only the drug.

In some cases, an additional step of derivatization is beneficial before the analysis
of the isolated drug. Derivatization is the process of chemically altering an analyte to
make it easier to detect or separate (Harris, 2007). Derivatization is used in this study to
improve the analyte's chromatographic behavior and assure its identification. Most
commonly used derivatizing reagents are bistrimethylsilyltrifluoroacetamide (BSTFA),
heptafluorobutyric anhydride (HFBA), pentafluoropropionic anhydride (PFPA), and
trifluoroacetic anhydride (TFAA). A study conducted by Cerilliant (2011) determined
that TFAA is the best derivatizing reagent to use with designer drugs such as
mephedrone.

In studies conducted on mephedrone, both methods have been used, but there
has been no specification of which is more conducive for the analysis of mephedrone.
The efficiency of either extraction method can be measured via analysis of mephedrone
with gas chromatography with mass spectrometric detection (GC-MS). GC-MS assays
can provide spectral analysis on mephedrone spiked synthetic urine samples. The
spectrum will provide information about the recovery of the extraction and detection
limits.
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CHAPTER II
REVIEW OF LITERATURE
Liquid-Liquid Extraction
Every step of drug analysis is critical, but preparation of the sample for analysis is
the most crucial part to achieving valid results. "Sample preparation is the series of steps
required to transform a sample so that it is suitable for analysis" (Harris, 2007, p. 655).
Sample preparation can consist of extraction of the desired drug from its matrix, making
the sample more concentrated so that it can be detected, or just dissolving the sample.
Extraction involves the dissolving of an analyte in a solvent without affecting the drug of
interest (Harris, 2007). Analysts attempt to control which direction the analysis can go
with each step they take in preparing the sample for analysis.
Liquid-liquid extraction, LLE, is the most commonly used method of extraction
because it is direct and blood and urine are the specimens that are frequently tested for
the determination of drugs. Because blood and urine are liquids, they are easily
"partitioned with an organic solvent without protein precipitation after a pH adjustment
of the liquid with a buffer, acid, or base" (Siek, 2010, p. 71 ). Polarity is the deciding
factor behind choosing an organic solvent for extraction of drugs. After deciding on the
proper organic solvent to use, a buffer is sometimes added so the drug of interest will be
in its non-ionic form and easily partition into the organic solvent of choice. The
adjustment of the pH before extraction depends on what class the drug falls in. Drugs are
classified into six classes: strong acids, weak acids, neutrals, weak bases, strong bases,
and amphoteric bases. When performing chromatographic assays such as HPLC, TLC,
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or GC, samples have to be extracted twice in order to have an extract that can be
chromatographed (Siek, 2010).
Solid Phase Extraction
To overcome the disadvantages of LLE, another method of extraction exists, solid
phase extraction. Harris (2007) describes solid phase extraction as a process in which a
solution is passed through a short column of chromatographic stationary phase to separate
the analyte from the matrix and the absorbed analyte on the column is eluted from the
column with a solvent. This method of separation is recorded to have existed since the
biblical days but has only been of scientific value and used as a technique since the 1970s
(Simpson, 2000).
The most important part in solid phase separation is the column. Columns were
developed in the 1960s and early '70s by bench toxicologists who developed their own
columns for separation (Siek, 2010). These columns contained sodium sulfate to absorb
water and shredded filter paper or cotton to retain the desired drug (Siek, 2010). This
somewhat successful method involved pouring blood through the column and afterwards
pouring a solvent through to recover the drug of interest (Siek, 2010). In October of
1977, the process became more convenient with the development of prepackaged,
disposable columns with bonded silica sorbents (Simpson, 2000).
The objective of solid phase extraction is for the analyte to be concentrated,
cleaned of unwanted molecules, and/or separated from the matrix (Simpson, 2000). An
isolated, cleaned, and concentrated drug is achieved through three steps. The first step is
retention, in which the analyte is separated from the matrix and retained by the sorbent
particles in the column. After retention of the analyte to the column, the column is
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washed with a solvent to remove any interfering compounds that can affect analysis.
Finally the analyte is eluted from the column with the passing of a solvent to desorb the
analyte and collect it in the solvent (Simpson, 2000).
Developed to overcome the challenges with liquid-liquid extraction, solid phase
extraction has its own disadvantages as well. In the case of drugs like benzodiazepines
and tricyclics, solid phase extraction uses more solvents, materials, and time. Although
this method is more tedious than liquid-liquid extraction, it compensates for that with its
reproducibility and minimizing the use of solvents (Siek, 2010). Unlike liquid-liquid
extractions that have to use immiscible solvents for the sample, solid phase extraction can
use miscible solvents (Simpson, 2000).
Mephedrone
Mephedrone has become an increasing problem in recent years, along with other
designer drugs. These designer drugs are synthetically made to possess similar effects to
the drugs from which they are derived while bypassing the laws that legally prohibit their
counterparts. Mephedrone (4-methylmethcathinone, 4-MMC) is a psychoactive
derivative of cathinone that provides similar results to those of stimulant and
hallucinogenic drugs. Cathinone is a naturally occurring alkaloid of the Khat plant,

Catha edulis, which originates in Northeast Africa and the Arabian Peninsula (National
Drug Intelligence Center, 2003). The derivatives of cathinones are the P-keto analogues
of the phenethylamine family (Drug Profiles, 2012).
Mephedrone is a ring substituted cathinone that differs from its phenethylamine
counterparts "by a keto functional group at the beta carbon" (Sedefov & Gallegos, 2011,
p. 27). Systematically named by IUPAC as (RS)-2-methylamino-l-(4-
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methylphenyl)propan-1-one, mephedrone's molecular formula, molecular weight, boiling
point, and melting point are: C 11 H 15NO, l77.242g/mol, 269.51 °C, and 66.61 °C
respectively (Sedefov & Gallegos, 2011).

Cathinone

Mephedrone

Amphetamine

Phenethylamine

Figure 1. Mephedrone and its related structures
Sedefov and Gallegos (2011) report that mephedrone was mentioned as early as
1929 by Saem de Bumaga Sanchez, who described its synthesis, mentioning it as toluyl-

alpha-monomethylaminoethylcetone. The straightforward synthesis of mephedrone
combines the product of brominated 4-methylpropiophenone with methyl amine and an
acid scavenger. Gaseous or aqueous hydrochloride is then added to provide the
hydrochloride salt that will need to be recrystallized. Mephedrone can also be
synthesized from the oxidation of 4-methylephedrine with potassium permanganate or
potassium dichromate (Sedefov & Gallegos, 2011). Methcathinone is synthesized from
the oxidation of ephedrine, which is also a precursor for methamphetarnine (Maheux et
al., 2010). Mephedrone is an analogue of methcathinone, which "is the ~-keto analog of
methamphetamine and the N-methyl derivative of cathinone" (Maheux et al., 20 l 0, p.
42). Because methcathinone is made from the same precursor of methamphetamine, and
mephedrone is the analogue of methcathinone, this can explain why mephedrone has
similar central nervous stimulatory effects as those of amphetamines. Mephedrone has
recently been scheduled as a schedule I drug in the United States.
Mephedrone, known as bath salts, appears as a white/slightly yellow powder or a
tablet and is most commonly administered via insufflation, but it can also be administered

9

orally, smoked, or intravenously (Drugs of Abuse, 2011). When taken orally in its
powder form, mephedrone is placed in cigarette paper and swallowed; this is referred to
as bombing (Prosser & Nelson, 2012). Mephedrone users report that after insufflation,
effects are experienced within 10 to 20 minutes and last about l to 2 hours. Users try to
overcome the quick comedown of insufflation by taking multiple doses (Schifano et al.,
2011). The desired effects of oral ingestion occur after 15 to 45 minutes of ingestion and

have duration of 2 to 4 hours (Prosser & Nelson, 2012). Because effects last longer with
oral ingestion, the need to take more doses to maintain that high is less than that of
insufflated mephedrone (Schifano et al., 2011 ). Users report that injection intravenously
provides effects within 10 to 15 minutes and tend to last 30 minutes (Prosser & Nelson,
2012).

Mephedrone produces stimulatory and hallucinogenic effects like that of
amphetamines and ecstasy, respectively. Although there are no published formal studies
on the psychological effects of mephedrone on humans, users do report effects that are
"broadly comparable to those reported for better-studied stimulant drugs" (Sedefov &
Gallegos, 2011, p. 29). The effects reported by mephedrone users are those of "euphoria,
general stimulation, enhanced music appreciation, elevated mood, decreased hostility,
improved mental function and mild sexual stimulation" (Sedefov & Gallegos, 2011, p.
29). Other than the desired pleasurable effects, users also experience adverse effects that

vary from agitation, depression, paranoia, and panic attacks (Drugs of Abuse, 2011 ).
Schifano et al. (2011) reported user complaints consisting of loss of appetite, nausea,
headache, dizziness, anxiety, agitation, elevated blood pressure, chest pain, and difficulty
urinating.
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Despite mephedrone having become increasingly popular over the recent years,
there is still much to be learned of its pharmacology and toxicity. A report from Sedefov
and Gallegos (2011) speculate that mephedrone acts as other stimulants by blocking
reuptake and stimulating the release of stimulant neurotransmitters such as serotonin,
dopamine, and norepinephrine. Support of this speculation is based on its chemical
structure and the similar sympathomimetic effects that are seen with mephedrone in
comparison to other stimulant drugs such as MDMA and cocaine (Sedefov & Gallegos,
2011). Martinez-Clemente, Escubedo, Pubill, and Camarasa (2012) determined that
mephedrone interacts with the transporters of dopamine and serotonin and blocks the
uptake of the neurotransmitters. The Encyclopedia of the Human Brain (2002) states that
serotonin affects sleep, mood, sexual behavior, and aggressive behavior; dopamine is
involved with the reward system and in addiction. Before studies on metabolism were
conducted, it was figured that mephedrone is "partly excreted as glucuronides and
sulphate conjugates" (Sedefov & Gallegos, 2011 , p. 58). Meyer, Wilhelm, Peters, and
Maurer (2010) concluded from a study on mephedrone's metabolism in human and rat
urine that mephedrone is partly excreted as glucuronides and/or sulfates.
Synthetic cathinones are less potent than their phenethylamine analogues due to
the ~-keto group increasing the polarity and allowing less chance for passage across the
blood-brain barrier (Drug Profiles, 2012). Although less potent and structurally similar to
amphetamines, there is still much more to be known about ring substituted cathinones.
There have been numerous reports of mephedrone related deaths and admittance to the
hospital for poisoning, but there is still no solid conclusion on the toxicity of
mephedrone. A case reported by the American College of Medical Toxicology
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determined that a male who had ingested 200mg of mephedrone and intramuscularly
injected 3.8g suffered from "isolated mephedrone toxicity" (Wood et al. , 2010, p. 329).
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CHAPTER III
METHODOLOGY
Method Overview
Synthetic urine samples were used for the purposes of this research. Two
milliliters of the synthetic urine were placed into 80 l 6x 120 screw cap tubes. Forty tubes
of the synthetic urine were spiked with 20µL of mephedrone to make a concentration of
0.5µg/mL; the remaining 40 tubes were spiked with 80µL, making a concentration
2.0µg/mL. Forty samples, which consisted of 20 tubes of 0.5µg/mL mephedrone and 20
tubes of 2.0µg/mL mephedrone, were extracted using liquid-liquid extraction (LLE). The
remaining samples were extracted using solid phase extraction (SPE). Each extract was
derivatized and injected into the Gas Chromatography-Mass Spectrometer (GC-MS)
under specific parameters. Results of the GC-MS analysis were used to compare LLE
and SPE to determine which method is more efficient. Spiked samples with
concentrations of 0.25µg/mL, 0.125µg/mL, and 0.05µg/mL were analyzed to determine
mephedrone ' s limits of detection for both extractions. Concentrations of 0.5µg/mL and
2.0µg/mL were used as neat standards with which to compare the extracted samples.
Preparation of Mephedrone Standard
A Mephedrone-HCl (Cerilliant, Round Rock, TX) standard with a concentration
of 1mg/mL was used to make dilutions of standards with the following steps:
1. lmL of lmg/mL mephedrone-HCl was added to a tube with 4mL of methanol

(MeOH) and vortexed for approximately 5-10, seconds making a concentration
of 200µg/mL.
2. lmL of 200µg/mL mephedrone was pipetted into another tube with 3mL of
MeOH to make 50µg/mL mephedrone.

I
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Preparation of Neat Mephedrone Standard
Mephedrone standards of 0.5µg/mL and 2.0µg/mL were used with which to
compare analyzed extracts. The neat standards were prepared by the following steps:
1. 2mL of MeOH were pipetted into two separate tubes.
2. 20µL of 50µg/mL standard were pipetted into one tube.
3. 80µL of 50µg/mL standard were pipetted into the other tube.
4. l OOµL of 0.1 % HCl were added to each tube and vortexed.
5. Each tube was place in a Rapidvap Labconco vacuum pump (Thermo-Fisher,
Houston, TX) and evaporated to dryness at 50°C for approximately l hour.
6. After drying, the standards were derivatized and dried again.
7. Once dry, lOOµL of ethyl acetate were added to the standards and vortexed.
8. The standards were transferred to autosampler vials containing 150µL inserts.
9. Vials were labeled, capped, and placed on the GC-MS for injection.
Preparation of Synthetic urine Samples
1. 2mL of synthetic urine were pipetted into 86 16xl20 screw cap tubes.

2. 20µL of the 50µg/mL standard were pipetted into 40 tubes containing
synthetic urine and vortexed for a concentration of 0.5µg/mL.
3. 80µL of the 50µg/mL standard were pipetted into 40 tubes containing
synthetic urine and vortexed for a concentration of 2.0µg/mL.
4. lOµL of the 50µg/mL standard were pipetted into 2 tubes containing synthetic
urine and vortexed for a concentration of 0.25µg/mL.
5. 5µL of the 50µg/mL standard were pipetted into 2 tubes containing synthetic
urine and vortexed for a concentration of 0.125µg/mL.
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6. 2µL of the 50µg/mL standard were pipetted into 2 tubes containing synthetic
urine and vortexed for a concentration of 0.05µg/mL.

Preparation of Sodium Hydroxide Solution
A l .OM solution of sodium hydroxide (Fisher Scientific, Houston, TX) was added
to the samples extracted via LLE to make the sample basic. The following steps were
completed to prepare lOOmL of I.OM sodium hydroxide (NaOH) solution:

1. 4. l g of NaOH were weighed out and placed into a 250mL Erlenmeyer flask.
2. lOOmL of Type m water (Millipore, Billerica, MA) were measured with a
graduated cylinder and added to the flask containing NaOH.
3. The flask was swirled until NaOH had dissolved.

Preparation of0.25M Phosphate Buffer
A 0.25M phosphate buffer was used to prepare the samples before SPE. The
phosphate buffer was prepared with both monobasic (NaH 2P04) and dibasic (Na2HP04)
sodium phosphate (Fisher Scientific, Houston, TX) by the following steps:

1. 6.90g of NaH2P04 were weighed out and placed in a 200mL Erlenmeyer fl ask
and dissolved to a final volume of 200mL with Type III water.
2. 13.40g of Na2HP04 were weighed out and placed in a 200mL Erlenmeyer
flask and dissolved to a final volume of 200mL with Type III water.
3. lOOmL of the 200mL of NaH2P04 were added to a clean beaker and placed on
a magnetic hot plate with a stirrer. 5mL of Na2HP04 were continuously added
to the beaker until a pH of 6.0 was achieved. The pH of the solution was
verified with a pH meter (Accumet 25CL, Fisher Scientific, Houston, TX).
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Preparation of 0.1 M Glacial Acetic Acid
AO. lM solution of Glacial Acetic Acid (Fisher Scientific, Fair Lawn, NJ) was
used with SPE for the washing of the sample. The following steps were completed to
prepare lOOmL of the solution:
l. 1OOmL of Type III water were measured with a graduated cylinder and poured
into a l OOmL Erlenmeyer flask.
2. 575µL of 17 .4M glacial acetic acid were pipetted into the flask.
3. The flask was swirled for thorough mixing.

Preparation of N-Butyl Chloride: Ethyl Acetate
An 80:20 dilution of N-Butyl Chloride: Ethyl Acetate (Fisher Scientific, Fair
Lawn, NJ) was used for both LLE and SPE to extract mephedrone. The solution was
prepared by the following steps:
l. 400mL of N-Butyl Chloride were measured using a graduated cylinder and
poured into a 500mL Erlenmeyer flask.
2.

lOOmL of ethyl acetate were measured and poured into the flask containing NButyl Chloride.

3. The flask was swirled to allow the two to be mixed.

Preparation of Triethylamine with N-Butyl Chloride: Ethyl Acetate
Four percent Triethylamine (TEA) (Fisher Scientific, Fair Lawn, NJ) prepared
with N-Butyl Chloride: Ethyl Acetate was used with SPE to elute the sample from the
column. The solution was prepared by the following steps:

1. 4mL of TEA were pipetted into a lOOmL volumetric flask.
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2. N-Butyl Chloride: Ethyl Acetate (80:20) was added until the volume was
brought to the l OOmL mark.
3. The flask was covered and inverted several times to allow adequate mixing.
Preparation of 0.1% Hydrochloric acid
Hydrochloric acid (Fisher Scientific, Fair Lawn, NJ) was used for both methods
of extraction during evaporation of the sample. Fifty milliliters of 0.1 % HCl were
prepared as follows:
l. 49.95mL of methanol were measured using a graduated cylinder and poured
into a 1OOmL Erlenmeyer flask.
2. 50µL of 6M HCL were added to the flask.
3. The flask was swirled for thorough mixing.
Preparation of 10% Hydrochloric acid
Hydrochloric acid was used to adjust the pH of the samples before SPE. The
following steps were completed to prepare 10% HCl:
l. A lOOmL volumetric flask was filled halfway with Type Ill water.
2. lOmL of HCl were added to the flask.
3. Type III water was added until the lOOmL mark was reached.
Liquid-Liquid Extraction of Mephedrone
Forty-three spiked synthetic urine samples, 20 of 0.5µg/mL, 20 of 2.0µg/mL, 1 of
0.25µg/rnL , 1 of 0.125µg/mL, and 1 of 0.05µg/mL were extracted via LLE by the
following steps:
l. lOOµL of l.OM NaOH solution were added to the sample and vortexed for
approximate Iy 5-10 seconds.
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2. 8mL of N-Butyl Chloride: Ethyl Acetate solution (80:20) were added to the
sample and capped.
3. The tubes were placed on a platform rotator for 30 minutes and mixed at a
slow speed to prevent emulsion.
4. The tubes were then centrifuged on a Sorvall Legend T + centrifuge (Fisher
Scientific, Houston, TX) at 3000 RPM for 10 minutes. After 10 minutes of
centrifuging, the tubes were bumped to remove the emulsion layer from the
sides of the tube and centrifuged for another 10 minutes.
5. The top layer containing N-Butyl Chloride: Ethyl Acetate was transferred to
clean l 6x 120mm tubes.
6. l OOµL of 0.1% HCl were added to each sample and vortexed.
7. The samples were evaporated to dryness at 50°C for approximately l.5 hours.
8. After drying, the samples were derivatized and dried again.
9. Once dry, lOOµL of ethyl acetate were added to the samples and vortexed.
10. The samples were transferred to autosampler vials containing 150µL inserts.
11. Vials were labeled, capped, and placed on the GC-MS for injection.

Solid Phase Extraction of Mephedrone
Solid phase extraction was performed on "No Vacuum" Gravity GV-65C columns
(Biochemical Diagnostics, Inc., Edgewood, NY). Forty-three spiked synthetic urine
samples, 20 of0.5µg/mL, 20 of2.0µg/mL, 1 of0.25µg/mL, 1 of 0 .125µg/mL, and l of
0.05µg/mL were extracted via SPE.

.
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Sample Preparation
1.

lmL of 0.25M sodium phosphate buffer (pH= 6) was added to each sample
and vortexed.

2. The samples were incubated at room temperature for 20 minutes.
3. 200µL of 10% HCl were added to the samples to adjust the pH to 2.
Column Conditioning
1. 43 columns were set up to sit inside l 6x 120 tubes to allow proper gravity

flow.
2. lmL of MeOH was added to each column to wash the column.
3. After the flowing of MeOH from the column, l mL of Type Ill water was
added.
4. Extraction of the sample was followed within 20 minutes of column
conditioning.
Sample Extraction
l. Each sample was poured onto a preconditioned column and allowed to flow
through completely.
2. 2mL of 0.1 M glacial acetic acid were added and allowed to flow through the
column.
3. 3mL of Type III water were added to wash the column.
4. lmL of MeOH was added to the column.
5. lmL of Ethyl Acetate was added to the column.
6. Columns were dried at 40°C for 15minutes
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Sample Elution
1. Each column was placed into clean test tubes for the elution of the sample.
2. l.5mL of N-Butyl Chloride: Ethyl Acetate (80:20) +4% Triethylamine were
added to each column.
3. 1OOµL of 0.1 % HCl were add~d to each tube and vortexed.
4. Each tube was evaporated to dryness at 50°C for approximately 1 hour.
5. Once dry, the samples were derivatized and dried again.
6. After drying, lOOµL of ethyl acetate were added to each tube and vortexed.
7. The samples were transferred to autosampler vials containing 150µL inserts.
8. Vials were labeled, capped, and placed on the GC-MS for injection.
Derivatization of Dried Samples
Before extracts were analyzed by GC-MS, the extracts were derivatized with
Trifluoroacetic anhydride (TFAA) (Acros Organics, New Jersey, USA) by the following
steps:
1.

lOOµL of TFAA were added to tubes containing dried extract.

2. 500µL of Toluene (Acros Organics, New Jersey, USA) were added to the
tubes, capped and vortexed.
3. The tubes were heated with caps on at 70°C for 30 minutes.
4. After heating, the tubes were allowed to cool for approximately 10 minutes.
5. The samples were uncapped and allowed to dry at 70°C for approximately 1.5
hours.
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CC-MS Analysis
Analysis was performed on a Perkin Elmer Clarus 600 Et AutoSystem GC with
built-in Autosampler (Shelton, CT).
CC Parameters
Autosampler Method
Syringe Capacity: 5.0µL
Injection: Auto
Injection Speed: Normal
Viscosity Delay: 0
Pre-Injection Solvent Washes: 2
Post-Injection Solvent Washes: 8
Injection Volume: 2µL
Sample Pumps: 2
Wash/Waste Vial Set: 1
Pre-Injection Sample Washes: l
Carrier Parameters
Carrier Control: He
Capillary column: MS5 30m x .25mm x 250µm phase
Vacuum Compensation: On
Flow Rate: 0.75mUmin
Initial Hold: 999.0 min
Heated Zones
Inlet A: CAP
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Setpoint: 250°C

Oven Program
Cryogenics: Off
Initial Temperature: I00°C
Maximum Temperature: 275°C
Initial Hold: 3.00 min
Equilibration Time: 0.3 min
Ramp: 25°C/min to 275°C, hold for O.Omin

Timed Events
Split 1: 0 at -0.20min
Split 2: 50 at 0.30min
MS Parameters

The MS analysis was performed on a PerkinElmer Clarus 600 Mass Spectrometer
(Shelton, CT).

Duration: 10.0 minutes
Solvent Delay Start: O.Omin
Solvent Delay End: 6.80min
Number of Functions: 1

Function 1: SIR of 3 masses
Time: 7 .00 to 8.50 minutes
Ion Mode:

Er

Scan Time: 0.25 seconds
Inter Scan Delay: 0.005 seconds
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Channel

Mass (Da)

Dwell (s)

1

91

0.050

2

119

0.050

3

154

0.050
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CHAPTER IV
DAT A AND RESULTS
A total of 86 tubes containing 2mL of synthetic urine were spiked with
mephedrone and used for this research. Forty of the samples were spiked with 20µL of
mephedrone for a concentration of 0.5µg/mL. The other forty were spiked with 80µL of
mephedrone for a concentration of 2.0µg/mL. The six remaining synthetic urine samples
were spiked with 10, 5, and 2µL of mephedrone to make two concentrations of 0.25,
0.125, and 0.05µg/mL, respectively. An average retention time of 7.69 was seen for the
majority of the extractions.
Neat standards of mephedrone were analyzed to compare to the mean area and
heights of extracted mephedrone to determine each method' s percent recovery. The
standards were prepared with 2mL of MeOH in each tube and 20µL and 80µL for
concentrations of 0.5µg/mL and 2.0µg/mL, respectively. The samples were dried with
IOOµL of 0.1% HCl at 50°C. Each standard was derivatized, dried at 70°C for about 1.5
hours, and analyzed by GC/MS using selective ion monitoring of the 91, 119, and 154 ion
fragments (see Figure 4). The mean, standard deviation, and standard error for the
standard concentrations were calculated using the peak area and height of the 119 ion
fragment (Tables 1 and 2). Two standards' chromatograms are displayed in Figures 2
and 3, showing areas and heights.

L

....
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Table 1

Mephedrone 119 Jon Area and Height of 0.5µg/ml Standard

0.5µg/mL Sample No.

0.5µg/mL Area

0.5µg/mL Height

l
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20

33,231
26,553
2 1,787
2 1,798
53,249
28,639
17,722
25,698
12,485
18,1 15
35,276
33,109
55,969
29,986
25,500
26,372
24,704
32,633
44,487
44,310

1,482,680
1,268,893
996,368
1,025,897
2,929,822
1,508, 190
835,784
1,307,290
599,602
833,576
1,324,995
1,434,687
2,755,932
1,431,726
1,168,998
1,266,032
1,227,282
1,682,028
2,45 1,025
2,423,222

30,58 1.1 50
1148 1.975
1862.622

1,497,701.450
647,064.558
104,967.732

Mean:
Std. Deviation:
Std. Error:

Note: Data for Standard 0.5µg/mL area and height of the 119 ion fragment. Results were used to determine percent recovery of LLE
and SPE.

LX

Mean=N

- 2

Standard Dev. =

r cx-X)

(N- 1)

Est. Std. Error =

so
J(N 1-l) + (N2 -l)
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Table 2

Mephedrone 119 Ion Area and Height of2.0µg/mL Standard

2.0µg/rnL Sample No.

2.0µg/rnL Area

2.0µg/mL Height

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20

214,484
165,478
136,548
119,981
96,626
150,156
94,8 13
219,481
150,330
122,241
229,9 14
100,121
83,749
185,437
9 1,256
184,296
2 14,065
109,247
206, 177
176,544

12,642,950
9,734,338
7,589,207
6,516,962
5,493,307
8,841,016
5,227,638
13,192,626
9,049,646
7,185,256
13,892,811
5,447,835
4,444,461
11,349,705
5,040,195
11 ,048, 184
12,976,743
6, 127,039
12,104,322
10,598,386

152,547.200
48,997.616
7,948.463

8,925,131.350
3,147,659.834
510,617.852

Mean:
Std. Deviation:
Std. Error:

Note: Data for Standard 2.0 µ g/mL area and height of the 119 ion fragment. Results were used to determine percent recovery of LLE
and SPE.
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Figure 2. Mephedrone chromatogram of neat standard 0.5µg/mL. Mephedrone was
eluted from the column at 7 .69 minutes. The peak integration shows an area of 33,231
and a height of 1,482,680.
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Figure 3. Mephedrone chromatogram of neat standard 2.0µg/mL. Mephedrone was
eluted from the column at 7 .69 minutes. The peak integration shows an area of 214,484
and a height of 12,642,950.
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Figure 4. TFAA derivatized Mephedrone ion spectra displaying the 119 ion fragment
which used for peak integration.
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LLE were performed on 20 of the 0.5µg/rnL, 20 of the 2.0µg/rnL, and 1 of each of
0.25µg/mL, 0.125µg/rnL, and 0.05µg/rnL. Each sample was treated with lOOµL of
NaOH to adjust the pH before extraction with 8rnL of N-Butyl Chloride: Ethyl Acetate
(80:20). The samples were placed on a platform rotator for 30 minutes and followed by
centrifugation for a total of 20 minutes. Halfway between centrifugation, the samples
were removed and bumped to remove the emulsion layer from the walls of the tube.
After centrifugation, the extraction solvent was removed and added to clean test tubes. In
order to reduce the loss of sample during evaporation, lOOµL of 0.1% HCI was added to
each sample. The extraction solvent was dried completely before derivatization at 70°C
for 30 minutes with 1OOµL of trifluoroacetic anhydride (TFAA) and 500µL of toluene.
The samples were dried and analyzed by GC-MS using selective ion monitoring of the
91 , 119, and 154 ion fragments. The mean, standard deviation, and standard error for
LLE of 0.5µg/rnL and 2.0µg/mL were calculated using the peak area and height of the
119 ion fragment (see Tables 3 and 4).
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Table 3

Mephedrone 119 lon Area and Height of0.5µglml LLE

0.5µg/mL Sample No.

119 ion area

119 ion height

1
2

582
1,721
2,187
2,643
1,299
1,499
5,444
990
2, 179
1,337
2,42 1
2,642
4,730
3,257
2,847
2,978
3,497
2,955
2,143
5,176

37,357
100,837
108,700
154,168
73,387
79,785
305,602
48, 175
113, 124
72,075
137,473
14 1,901
263,716
180,919
160,735
175, 193
194,397
172,803
124,263
287,616

2626.350
1324.717
2 14.898

146611.300
74819.919
12137.394

3

4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
Mean:
Std. Deviation:
Std. Error:

Note: Data fo r LLE of 0.5µ g/mL area and height of the l l 9 ion fragment. Results were used to establish any significant difference
compared to S PE.
- 2

Standard Dev. =

l:(X-X)
(N-1)

50

== =
J(N1- l)+(Nz-1)

Std. Error = -;==
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Table 4

Mephedrone 119 Ion Area and Height of2.0µg/mL LLE

2.0µg/mL Sample No.

119 ion area

119 ion height

l
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20

5289
21,6 18
29,385
34,932
32,404
35,050
83,053
106,410
55,559
150,682
209,051
88,895
84,467
195,287
177,427
225,729
227,575
209,289
169,992
193,712

376,515
1, 124,926
1,577,971
1,863,275
1,788,215
1,903,884
4,649,702
6,243,251
2,993,259
8,605, 144
11 ,926,742
4,806,430
4,502,916
10,462,803
9,9 15,483
12,308,8 18
13,088,955
11,666,571
9,269,243
10,624,808

116790.300
78604.595
12751.349

6484945.550
4400128.071
713795.029

Mean:
Std. Deviation:
Std. Error:

Note: Data for LLE of 2.0µg/mL area and height of the 11 9 ion fragment. Results were used to establish any significant difference
compared to S PE.

---

ltnr
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SPE were performed on the remaining samples: 20 of the 0.5µg/mL, 20 of the
2.0µg/mL, and 1 of each of 0.25µg/mL, 0.125µg/mL, and 0 .05µg/mL. One mL of l .OM
sodium phosphate buffer (pH = 6) was added to each sample and incubated at room
temperature for 20 minutes. To acidify the sample before extraction, 200µL of 10% HCl
was added to each sample. The samples were poured onto columns that were
preconditioned with lmL of MeOH and lmL of type III water. The samples were
washed with 2mL of O. lM glacial acetic acid, 3mL of type Ill water, lmL of MeOH, and
lmL of ethyl acetate, allowing for each solvent to flow through completely. The columns
were dried at 40°C for 15 minutes. To elute the samples, l.5mL of N-Butyl Chloride:
Ethyl Acetate + 4% TEA were added to each column. One hundred microliters of 0.1 %
HCl was added to the eluent and evaporated to dryness at 50°C for l hour. The dried
samples were derivatized at 70°C for 30 minutes with lOOµL of trifluoroacetic anhydride
(TFAA) and 500µL of toluene. The samples were dried and analyzed by GC-MS using
selective ion monitoring of the 91, 119, and 154 ion fragments. The mean, standard
deviation, and standard error for SPE of 0.5µg/mL and 2.0µg/mL were calculated using
the peak area and height of the 119 ion fragment (see Tables 5 and 6).

r
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Table 5

Mephedrone 119 Jon Area and Height of0.5µ g/mL SPE

0.5µg/mL Sample No.

11 9 ion area

119 ion height

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20

1,967
6,217
3,093
5,563
3,425
3, 138
2,985
5,014
4,255
6,39 1
3,841
6,444
3,981
4,4 11
2,722
6,165
3,22 1
5,533
3,797
4,562

153,399
362,220
183,960
341,736
197,614
186,997
177,646
312,828
266,559
397,219
235,206
41 1,544
243,242
265 ,679
159,094
383,4 12
191,361
340,534
229,480
274,576

4336.250
1352.750
2 19.445

2657 15.300
83645.771
13569.1 36

Mean:
Std. Deviation:
Std. Error:

Note: Data for SPE of 0.Sµg/ mL area and height of the 119 ion fragment. Results were used to establish any significant difference
compared to LLE.

32
Table 6

Mephedrone 119 Ion Area and Height o/2.0µg/ml SPE

2.0µg/mL Sample No.

119 ion area

119 ion height

1
2
3
4
5

17,539
34,427
33,617
21,767
33,940
19,630
15,088
18,993
22,368
21,823
22,081
28,125
17,402
7,507
28,346
25,874
25,486
31,485
27,544
28,237

966,463
1,958,788
2,035,855
1,310,7 13
2,040,852
1,153,008
894,503
1,138, 131
1,385,448
1,304,416
1,353,607
1,749,587
1,043,270
450,643
1,646,558
1,612, 155
1,575,600
1,875,4 17
1,647,794
1,739,522

24063.950
6977.600
1131.916

1444116.500
421209.818
68329.255

6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
Mean:
Std. Deviation:
Std. Error:

Note: Data for SPE of 2.0µg/mL area and height of the 119 ion fragment. Results were used to establish any significant difference
compared to LLE.
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Concentrations of 0.25µg/mL, 0.125µg/mL , and O.OSµg/mL were extracted via
LLE and SPE to determine mephedrone's limit of detection for each method (see Tables
7 and 8).
Table 7

Mephedrone 119 Ion Area and Height of LLE 0.25µg/mL, 0. 125µg/mL , and 0.05µglmL

119 Ion Area

119 Ion Height

0.25µg/mL

5,834

327,251

0.125µg/mL

2,727

135,488

O.OSµg/mL

2,523

134,183

Concentration of Sample

Note: Data of LLE of 0.25µg/mL. O. l 25µ g/mL and 0.05µg/mL to determine mephedrone's li mit of detect.ion for LLE.

Table 8

Mephedrone 119 Ion Area and Height of SPE 0.25µ glmL, 0. 125µg/mL, and 0.05µ g/mL

Concentration of Sample
0.25µ g/mL
0. 125µg/mL
O.OSµ g/mL

119 Ion Area

119 Ion Height

1,489

98,848

572

38,432

16 1

9,897

Note: Data of SPE of 0 .25µg/mL. O. l 25µg/ mL. and 0.05µ g/mL to determine rnephedrone·s li mit of detection for S PE.
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To determine if there was a statistical difference between LLE and SPE, a t test
was completed at the .05 level of confidence. The standard error of difference for area
and height of both concentrations and methods was calculated and used to determine a t
ratio. Compared to at value of 2.086, the t ratio was outside of the 0.5 confidence level,
signifying that LLE and SPE are significantly different (see Tables 9 and 10).
Table 9

Statistical Comparison of LLE and SPEfor 0.5µ g/mL

Standard Error Standard Error of Difference

Mean
LLE Area

2626.35

214.898

SPE Area

4336.25

219.445

LLE Height

146611.30

12137.394

SPE Height

265715.30

13569.136

f(.05)(100)

307.143

5.567

18205.433

6.542

Note: Statistical comparison of 0.5µg/mL LLE and SPE. With a degree of freedom of 19. the I value is 2.086. The t ratios fo r
0.5µg/mL are larger than the I value , mean ing that LLE and S PE are significantly different for this concentration.

Std. Error Difference =

j (SE

2
1

+ SE 2 2 )

T
35
Table 10
Statistical Comparison of LLE and SPE f or 2.0µg/mL

Mean

Standard Error Standard Error of Difference

LLE Area

116790.30

12751.349

SPE Area

24063.95

1131.916

LLE Height

6484945.55

713795.029

SPE Height

1444116.50

68329.255

t(.OS)( IOO)

12801.490

7.243

717058.038

7.030

Note: Statistical comparison of 2.0µg/mL LLE and SPE. With a degree of freedom of 19. the t value is 2.086. The t ratios fo r
2.0µg/mL are larger than the I value. meaning that LLE and SPE are significantly different for this concentration.

Percent recovery shows the percentage of analyte that is recovered from each
method based off of the samples ' peak area and height. Peak integration was performed
on the 119 ion fragment to provide the samples' area and height. The average of
0.5µg/mL and 2.0µg/mL area and height for both methods were compared to
mephedrone' s average standard area and height to achieve a percentage (Tables 11 and
12)
Table 11
Percent Recovery for 0.5µ glmL Mephedrone Extraction

Mean

Percent Recovery

Standard Area

30581.15

LLE Area

2626.35

8.59%

SPE Area

4336.25

14.18%
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Table 11 (continued.)

Mean

Percent Recovery

Standard Height

1497791.45

LLE Height

146611.30

9.79%

SPE Height

265715.30

17.74%

Note: Percent recovery of 1 19 ion fragme nt for LLE and SPE of 0.5µg/mL. SPE has a higher percentage of recovery than LLE:
therefore, SPE is a more effi cient method for 0.5µg/mL mephedrone.

Percent Recovery=

Extraction~
( Stan dar d X

x 100

Table 12

Percent Recovery f or 2.0µ g/ml Mephedrone Extraction

Mean

Percent Recovery

Standard Area

152547.20

LLE Area

116790.30

76.56%

SPE Area

24063.95

15.77%

Standard Height

892513 1.35

LLE Height

6484945.55

72.66%

SPE Height

1444116.50

16.18%

Note: Percent recovery of 119 ion fragment fo r LLE and SPE of2.0µg/ mL. LLE has a higher percentage of recovery than SPE:
therefore. LLE is a more efficient method for recovery of 2.0µg/mL mephedrone.
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CHAPTER V
DISCUSSION
Mephedrone is currently one of the more popular designer drugs of today. Its
stimulatory and hallucinogenic effects provide a high like that of amphetamines and
ecstasy. With its increasing popularity, it is imperative that efficient methods of analysis
are employed in an attempt to keep up with the designer world. This study was
conducted with goals of confirming that one method of extraction is more efficient and
conducive to obtaining knowledge of mephedrone
Liquid-liquid extraction is the oldest and most widely used method of extraction.
The use of two immiscible liquids appears to be fairly simple, but can be time consuming
and costly due to the large amounts of solvents used. Although not as old in the scientific
world as LLE, solid phase extraction involves the use of columns and smaller amounts of
solvents.

In this research, the derivatization of mephedrone prior to analysis proved to be a
crucial step in detecting the analyte from the extracts. Initially LLE and SPE were
conducted on all synthetic urine samples, with no success for SPE. LLE analysis
detected mephedrone and displayed peaks that could be integrated. SPE, however, gave
distorted chromatograms with no ability to identify mephedrone. Derivatization was
applied to help identify mephedrone because of is small molecular weight of
177.242g/mol.
This experiment focused on determining the more efficient method for the
extraction of mephedrone from synthetic urine. It was theorized that LLE would be the
more efficient method compared to SPE in the recovery of mephedrone. Because
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mephedrone is a designer drug, there was concern that the use of columns specified for
amphetamine drug testing may not be successful. After numerous trial runs, SPE
demonstrated its ability to extract mephedrone just as LLE method. Manufacturer's
directions did not specify to dry the columns prior to elution of the sample, but this
technique was the determining factor in GC-MS detecting mephedrone from SPE
extracts.
Eighty mephedrone spiked synthetic urine samples were extracted; 20 of
0.5µg/mL and 20 of 2.0µg/mL were extracted via LLE and 20 of 0.5µg/mL and 20 of
2.0µg/mL were extracted via SPE. A two tail T-test was completed on the average areas
and heights of the analyzed samples. The t ratio of area and height of each extraction
were compared to at value of 2.086 with a confidence level of .05 and 19 degrees of
freedom. The t ratios for LLE and SPE of 0.5µg/mL were 5.567 and 6.542 for area and
height respectively. For LLE and SPE of 2.0µg/mL , the t ratio was calculated to 7 .243
for area and 7 .030 for height. The t ratios for both extractions and concentrations falling
under the t value signify that LLE and SPE are significantly different for the extraction of
mephedrone.
The areas and heights of the analyzed samples were used to determine which
method was more efficient in recovering mephedrone from synthetic urine. Standards of
0.5µg/mL and 2.0µg/mL that were not extracted, were derivatized and analyzed 20 times
each just as the extracts were. The results of the standards' areas and heights were
compared to the average areas and heights of the extracted samples of both methods. The
results concluded that for 0.5µg/mL , SPE is more efficient with a recovery of 14.18% and
17.74% for area and height compared to LLE 8.59% and 9.79%. For 2.0µg/mL, LLE
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percent recovery is better than that of SPE. LLE percent recovery for area and height are
76.56% and 72.66% while SPE percentages are 15.77% and 16.18%.
Additional samples of 0.25, 0.125, and 0.05µg/mL were extracted via both LLE
and SPE to determine mephedrone's limit of detection with analysis of GC-MS. For
LLE, a steady decrease in peak area and height is seen with the decreasing
concentrations. SPE peak area and height also show an area and height decrease with
decreasing concentration. The peak areas and heights are smaller for SPE than LLE. In
both cases, mephedrone is still detected at only 0.05µg/mL. For toxicological purposes,
there is no need to test lower than this limit.
There is a large variation in the data received, which may be due to inconsistent
derivatization of the extract. Capacity limits of SPE gravity flow columns may present an
issue as well for extracting concentrations beyond 0.5µg/mL. Research would need to be
conducted to determine the capacity of this column. The factor of varying results may
have been able to be pinpointed had an internal standard been used in this research. In
this study, however, there were issues with obtaining an appropriate internal standard for
extraction of mephedrone. In the areas of derivatization, column capacity, and use of an
internal standard, further research is needed.
This study exhibited that for the extraction of mephedrone spiked synthetic urine,
SPE is a better extraction method than LLE in the case of extracting concentrations lower
than 2.0µg/mL. If extracting larger concentrations of 2.0µg/mL and beyond, LLE
appears to be the better method. Although both methods serve the same purpose of
extracting analytes from mediums, they are significantly different. Further studies on this
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research would be beneficial to analysts to ensure they are getting the most out of their
analysis as well as to the human performance arena of forensic toxicology.
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